Therapeutic Value Assessments of Novel Medicines in the US and Europe, 2018-2019
Open Access
- 6 April 2022
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (4) , e226479
Abstract
The rate of new drug approvals by the US Food and Drug Administration (FDA) has increased over the past decade.1 One factor contributing to this increase in number of drugs entering the market is the expedited regulatory review programs that the FDA and European Medicines Agency (EMA) have established to speed access to new treatments.2 For example, the accelerated approval (AA) program permits the FDA to approve novel drugs for serious or life-threatening diseases on the basis of changes to surrogate measures that only are reasonably likely to predict clinical benefit.2 Surrogate measures are laboratory values that can be observed faster than clinical end points but may not accurately estimate how a patient feels, functions, or survives.3 The analogous approval pathway in the European Union (EU) is the conditional marketing authorization (CMA). Special designations in the US and Europe are also available for drugs addressing rare diseases and promote regulatory flexibility when evaluating the evidence.4Keywords
This publication has 4 references indexed in Scilit:
- Fulfilling the Mandate of the US Food and Drug Administration’s Accelerated Approval PathwayJAMA Internal Medicine, 2021
- Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort studyBMJ, 2020
- Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugseClinicalMedicine, 2020
- Reforming the Orphan Drug Act for the 21st CenturyNew England Journal of Medicine, 2019